“Stephen’s superb and seasoned talent for customer engagement and support are a timely addition as we bring the Reveal rapid AST system to hospitals and labs around the UK.”
MOUNTAIN VIEW, Calif. (PRWEB) November 10, 2020
Specific Diagnostics today announced the appointment of Stephen Abel as Head of Commercial Operations, UK, as it rapidly expands its commercial operations in Europe. Mr. Abel brings two decades of successful commercial experience to Specific, having served as Beckman Coulter’s UK Business Development Manager for Urinalysis for the past 8 years. Prior to Beckman Mr. Abel was UK Sales Manager at Iris Diagnostics for 4 years and Product Specialist for 2 years at Instrumentation Laboratory. UK. Mr. Abel will oversee the implementation of Specific’s commercial strategy in England and Ireland, joining the commercial team led by Anthony Bazarko, CCO and Alain Richard, Head of European Operations.
“With our CE-IVD registration we have rapidly moved to evaluation sites in France and Germany, and are now looking to expand to the UK,” said Dr. Paul A. Rhodes, Specific’s CEO. “Stephen’s superb and seasoned talent for customer engagement and support are a timely addition as we bring the Reveal rapid AST system to hospitals and labs around the UK.”
“I am thrilled to join Specific at this dynamic time for infectious disease diagnostics,” said Mr. Abel. “I have spent many years in microbiology diagnostics in the UK market, and am certain that Specific’s rapid susceptibility testing product has the affordable cost, simplicity of use, and throughput that my customers require, and that its introduction will be of immediate benefit to patients threatened by blood infection.”
While at Beckman Coulter, where he received the Inner Circle UK Sales award in 2015 and 2018, Mr. Abel introduced the Beckman Coulter ID/AST product into UK market. At Iris Diagnostics he oversaw the UK territory, oversaw tenders, and managed service contract requirements. Mr. Abel received a BSc with honors in Biological Sciences from the University of Hull and was awarded the Queens Commission while serving in the Royal Airforce as a Flying Officer.
Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they grow in culture. Its first commercial application applies this fundamental new platform to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions. Specific is based in Mountain View, CA.
For press inquiries, please contact: firstname.lastname@example.org